Logo

Forty Years of Solitude: Landmark Results from the S31/A5349 trial of Shortened Treatment for Drug-Susceptible Tuberculosis - Shared screen with speaker view
HU CFAR
21:36
GO
Nicole Frahm
27:51
someone is making a lot of noise
Marcia Goldberg
28:15
Please mute all who are not speaking.
Eric Rubin
28:52
I think that attendees can’t speak anyway.
HU CFAR
29:02
I believe it is the speaker's headset cable
Nicole Frahm
29:48
her cable is not moving
Nicole Frahm
29:56
when the noise is present
Rajesh Gandhi
34:02
Alberto, there's some background static (intermittent). Is that from one of the mics?
HU CFAR
35:23
i believe susan is brushing the cable to her headset when she's moving to forward slides? it's a guess.
Marcia Goldberg
35:27
I’m getting a lot of intermittent static - perhaps from he speaker’s mic itself. Perhaps someone could let her know?
HU CFAR
37:00
Gustavo, if this persists, please let susan know about the disturbance
Gustavo Velasquez
37:11
OK
Gustavo Velasquez
50:46
Alberto, some attendees are raising their hands to ask questions (e.g., Paul Sax). Are you able to unmute them or should we ask all questions come via chat?
Gustavo Velasquez
51:39
OK. I think I saw Mary G. first, then Paul Sax
Gustavo Velasquez
52:11
no, during Q&A at end
Gustavo Velasquez
52:20
I will send out a message to attendees now
Gustavo Velasquez
53:41
Attendees— the co-moderators and I will take questions via chat and can ask the presenters your questions, and for the two of you who have raised your hands we will call on you and unmute you if you want to speak. Thank you.
Gustavo Velasquez
54:12
We’ll wait to take questions until after Dr. Chaisson’s talk.
HU CFAR
01:04:17
Raj, I'll invite you to speak during the Q&A if OK with you and have a question
HU CFAR
01:04:52
Galit, i'll invite you to speak during the Q&A if you wish and have a question
Rajesh Gandhi
01:05:03
Sure, Thanks
HU CFAR
01:08:30
Hi Paul, I'll invite you to speak once we start the Q&A session. Are you ready?
Paul Sax
01:09:51
Do you mean me? or a different Paul? This is a great series of talks!
Gustavo Velasquez
01:10:22
Rocio, Amy— I can take the first question and call either on Paul or Raj to speak
HU CFAR
01:10:38
I mean you, Paul Sax
Amy Barczak
01:10:46
Yes Gustavo-
HU CFAR
01:11:01
unless you raised your hand by mistake
Paul Sax
01:11:09
mistake, sorry!
Gustavo Velasquez
01:11:35
OK, I will call on Raj first and invite people to put questions in chat or raise their hands
HU CFAR
01:11:49
OK, not problem
Amy Barczak
01:11:57
Raj I think Gustavo is going to call on you first if you have a question-
Amy Barczak
01:12:10
OK?
Rajesh Gandhi
01:12:22
Sounds good
Amy Barczak
01:14:07
Gustavo before you call on Raj, do you want to remind people to post questions or raise their hands?
Gustavo Velasquez
01:14:12
Yes will do
Mark Siedner
01:14:23
Thanks Gustavo and the organizers of this talk. First off - a serious congratulations to the team on this field-changing work. A couple questions for the authors if there is time:1. In thinking about how to convert these findings to practice in settings like SSA, how was DOT done in practice in the study - community/home-based or clinic-based? For the entire 4 month regimen?2. For relevance in the US (and hopefully one day SSA) are there data on bictegravir, doravarine with these regimens?
Amy Barczak
01:15:00
Rocio do you want to ask Mark
Amy Barczak
01:15:06
s questions next?
Rocio Hurtado
01:15:18
yes i can summarize and ask his questions
Eric Rubin
01:15:31
Congratulations on a terrific outcome! A question for any speaker. TB treatment programs have been critical for getting therapies to people. But they’re not famously flexible. Once the WHO endorses the therapy, how do you see implementation being carried out?
Paul Sax
01:16:49
Great data, and wonderful talks! We’re in a “fear of quinolones” era, and so are loathe to give prolonged courses, especially to the elderly, unless absolutely needed. I saw that the median age of the participants was roughly in their 30s. Do you feel the trial had enough older patients to address these FQ concerns?
HU CFAR
01:17:51
do you want to say something? Gustavo is asking
Amy Barczak
01:18:39
I’m happy to ask Eric’s question next-
Gustavo Velasquez
01:18:44
Sounds good.
Rocio Hurtado
01:18:55
gustavo can you do paul’s or invite him
Gustavo Velasquez
01:19:34
Yes I’ll take Paul’s. He put his hand down before so I will read it out. We are close to the hour, will be go to 5 minutes after?
Mark Siedner
01:19:41
Thank you
HU CFAR
01:20:00
Paul, Rocio is asking to engage you. are you willing?
Karen Jacobson
01:21:03
Any concern for vulnerability to baseline resistance compared to RIPE? If INH or fluoroquinolone resistance at baseline? Need for testing beyond rif?
Paul Sax
01:21:10
Sure.
Rocio Hurtado
01:21:32
i can ask Karen Jacobson’s q
Amy Barczak
01:21:40
Wrong Paul enabled- can you enable Paul Sax?
Gustavo Velasquez
01:21:41
Paul Sax not Converse
HU CFAR
01:22:17
sorry paul, i meant to engage the other paul.
Paul Converse
01:23:07
Thanks, No problem!
Gustavo Velasquez
01:23:34
Rocio, Karen’s then close?
Amy Barczak
01:23:43
Agree-
Amy Barczak
01:23:55
Rocio we’ll defer to you to do the closure after the answer to this question.
Rocio Hurtado
01:24:30
ok if no more then i can close